Active topical skin protectants containing amines, polyalkenimines and /or derivatives

ABSTRACT

A topical skin protectant formulation containing a barrier cream and an active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWA). The active moiety is an amine, polyalkenimines and/or derivatives. The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.

[0001] The invention described herein may be manufactured, used and licensed by or for the U.S. Government. This application claims priority of provisional application No. 60/378,443 filed May 6, 2003.

BACKGROUND OF THE INVENTION

[0002] 1. Field of the Invention

[0003] This invention relates to active topical skin protectants. More specifically, the invention relates to an active barrier cream for protection against all types of harmful chemicals, specifically chemical warfare agents (CWAs). The active barrier cream is applied prior to exposure on the skin of persons at risk of exposure to harmful chemicals to provide a protective barrier for the skin. The active barrier cream chemically or physically reacts with harmful chemicals such as CWAs (vesicants and nerve agents) to neutralize these harmful chemicals while the barrier properties of the cream prevent penetration of harmful chemicals through the cream to the skin.

[0004] 2. Description of Related Art

[0005] The concept of applying a topical protectant to vulnerable skin surfaces before entry into a chemical combat arena has been proposed as a protective measure against percutaneous CWA toxicity since the first use of CWA in World War I. The protectant was applied to vulnerable skin surfaces prior to entry into a chemical combat area. Topical protectants should augment the protection afforded by the protective over garments and/or redefine the circumstances requiring mission oriented protective posture (MOPP) levels. The rapid action of vesicating agents, also known as blistering agents, such as sulfur mustard (HD) and lewisite (L), require a pre-exposure skin protection system or a contamination avoidance approach that may preclude the percutaneous toxicity of these agents. These approaches also reduce the risk of exposure to organophosphorus (OP) chemical agents (nerve agents), which unlike the vesicating agents are lethal in droplet amounts.

[0006] An organic molecule, S-330, that reacts with CWA was incorporated into a product and fielded as the M-5 ointment kit at the end of World War II (Formula 1).

[0007] However, the unacceptable barrier properties and the undesirable cosmetic properties (specifically foul odor and sticky texture) caused a recall of this product.

[0008] Two non-active topical skin protectant (TSP) formulations were developed at the United States Army Medical Research Institute of Chemical Defense (USAMRICD) and were transferred to advanced development following a Milestone Zero (MS0) Review in October 1990. The timeline of the approval of the TSP continued with MSI in 1993, a Investigational New Drug (IND) filed with the FDA in 1994, MSII in 1995, and culminated with New Drug Application (NDA) approval in February, 2000. Upon approval by the FDA, the TSP was designated Skin Exposure Reduction Paste Against Chemical Warfare Agents (SERPACWA). SERPACWA is a 50:50 (wt/wt) mixture of perfluoropolyether oil (Fomblin® Y25 from Ausimont) and poly(tetrafluoroethylene) (Polymist® F5a powder from Ausimont). The formulation described in McCreery U.S. Pat. No. 5,607,979 is directed to a topical skin protectant cream that acts as a barrier to CWA.

[0009] Although SERPACWA extends the protection afforded by MOPP and allows a longer window for decontamination, it does not completely remove the possibility for contamination because the CWA is not neutralized. To avoid contamination of other areas of the battlefield and to preclude the future percutaneous absorption of the CWA, decontamination is still required. Furthermore, although the McCreery formulation provides excellent protection against soman (GD) and sulfur mustard (HD) liquid, its protection against GD and HD vapor is minimal.

[0010] To overcome these deficiencies, there is a need for a new TSP that contains an active component. This active Topical Skin Protectant (active TSP, aTSP) was developed within the following criteria. First, the active TSP should neutralize CWA including but not limited to HD, GD, and VX. Second, the barrier properties of the TSP should be maintained or increased. Third, the protection against GD and HD vapor should increase. And fourth, the cosmetic characteristics (i. e. odor, texture) of the TSP should be maintained.

[0011] This invention meets the above criteria and solves the problems associated with the past TSPs by providing an active topical skin protectant that increases effectiveness of the TSP barrier quality and neutralizes CWA into less harmful products.

[0012] It is therefore, an objective of the present invention to provide an active topical skin protectant that prevents the percutaneous absorption of CWA and converts these toxic materials into less harmful products.

[0013] It is a further objective of the present invention to provide an active topical skin protectant that maintains desirable cosmetic properties making it acceptable to the user. Specifically, the active TSP should not be sticky, should be without offensive odor, and should be nonirritating to the skin.

[0014] It is still a further object of the invention to provide an active topical skin protectant that is practical for field operations. Specifically, the active TSP should have a stable shelf life, not be easily washed off with water, and should not react with insecticides or camouflage paint.

SUMMARY OF THE INVENTION

[0015] A topical skin protectant formulation for neutralizing chemical warfare agents into less toxic products comprising: a barrier base cream and one or more active moieties. The base cream comprises poly(tetrafluoroethylene) resins dispersed in perfluorinated polyether oils. A chemical family of active moieties that has been found to be very effective with the base cream is the polyalkenimines. Effective formulations containing polyalkenimines and other active materials in the base cream are listed in Table 1. The active barrier cream is applied to the skin prior to exposure of persons at risk of exposure to harmful chemicals to provide an active barrier to protect the skin. The active barrier cream chemically or physically reacts with harmful chemicals such as CWA to neutralize these harmful chemicals while the barrier properties of the cream prevent penetration of harmful chemicals through the cream to the skin.

BRIEF DESCRIPTION OF THE DRAWINGS

[0016]FIG. 1 is a flow diagram of the active TSP Decision Tree Network for efficacy evaluation;

[0017]FIG. 2 is series of ³¹P NMR Spectra that measures the hydrolysis of Phosphorofluoridic acid diisopropyl ester (DFP) in D₂O with 2.5 wt % Lupasol WF (ICD 3732);

[0018]FIG. 3 is the ¹H NMR spectrum of 2-chloroethylethylsulfide (CEES) in d₆-DMSO;

[0019]FIG. 4 is the ¹H NMR spectrum of 2-chloroethylethylsulfide (CEES) in d₆-DMSO+100 eq D₂O after 18 h;

[0020]FIG. 5 is the ¹H NMR spectrum of CEES+2.5 wt % Lupasol WF (ICD 3732) in 100 eq D₂O in d₆-DMSO after 12 h;

[0021]FIG. 6 is a graph showing GD vapor penetration cell data of a 0.15 mm thick aTSP barrier in 20 hours;

[0022]FIG. 7 is a graph showing HD vapor penetration cell data for the cumulative amount of HD vapor through active TSP over 20 hours;

[0023]FIG. 8 is a graph showing a M8 paper test of the time to GD and HD liquid breakthrough for active TSPs containing polyalkenimines;

[0024]FIG. 9 is a graph showing HD liquid and GD liquid penetration cell data of the cumulative amount of HD and GD liquid through active TSP” over 20 hours;

[0025]FIG. 10 is a graph showing HS-SPME/GC-MS;

[0026]FIG. 11 is a graph comparing polyalkenimines at 2.5wt % in D₂O solution against DFP challenge;

[0027]FIG. 12 is a graph showing results of active TSPs containing polyalkenimines;

[0028]FIG. 13 is a graph showing GD vapor rabbit lethality test giving results of active TSPs containing polyalkenimines;

[0029]FIG. 14 is a graph showing VX liquid rabbit lethality test giving results of active TSPs containing polyalkenimines.

DETAILED DESCRIPTION

[0030] Candidate Active Moieties

[0031] The types of materials that neutralize harmful agents use three main modes of action: oxidation, reduction or hydrolysis.

[0032] Operating criteria, however, restricts the selection of the active materials. Thus, the active moiety must not irritate the skin, react with insecticides or camouflage paints or be lack thermal or temporal stability. This restriction eliminates many of the most active species. Furthermore, the active moiety must be incorporated into a highly fluorinated environment that is not amenable to many reaction pathways.

[0033] Table 1 is a list of formulations containing amines, polyalkenimines and/or its derivatives and other active materials that are acceptable for use in the present invention: TABLE 1 LIST OF AMINES, POLYALKENIMINES AND/OR DERIVATIVES FOR ACTIVE TOPICAL SKIN PROTECTANTS ICD # Active Moiety % Active % Other % PFPE % PTFE 3470 Lupasol P (ICD3720) 10 Fluorolink 7004 38 43 (ICD3719) 2% Water 7% 3471 Lupasol P (ICD3720) 15 Fluorolink 7004 27 49 (ICD3719) 3% Water 6% 3630 DEAM (ICD3604)  2 Light Surfactant 49 46 (ICD 2853) 1% Water 1% 3631 DEAM (ICD3605)  2 Light Surfactant 48 48 (ICD 2853) 1% Water 1% 3632 DEAM (ICD3606)  2 Light Surfactant 49 47 (ICD 2853) 1% Water 1% 3712 Lupasol P (ICD# 3720)  9 Fluorolink 7004 48 32 (ICD3719, 3%), water (8%) 3713 Lupasol P (ICD# 3720)  7 Fluorolink 7004 48 32 (ICD3719, 3%), water (10%) 3714 Lupasol P (ICD# 3720) 20 Fluorolink 7004 60 15 (ICD3719, 2%), water (3%) 3715 Lupasol P (ICD# 3720) 25 Fluorolink 7004 45 21 (ICD3719, 2%), water (7%) 3716 Lupasol P (ICD# 3720) 25 Fluorolink 7004 43 25 (ICD3719, 2%), water (5%) 3717 Lupasol P (ICD# 3720) 25 Fluorolink 7004 40 30 (ICD3719, 2%), water (3%) 3718 Lupasol P (ICD# 3720) 25 Fluorolink 7004 35 30 (ICD3719, 2%), water (3%) 3728 Lupasol P (ICD# 3720) 20 55 25 3729 Lupasol P (ICD# 3720) 20 40 40 3742 Lupasol P (ICD# 3720) 26 Fluorolink 7004 38 33 (ICD#3719, 3%) 3743 Lupasol P (ICD# 3720) 26 Fluorolink 7004 38 33 (ICD#3730, 3%) 3746 Lupasol SC (ICD# 3731) 10 Fluorolink 7004 40 45 (ICD3719, 2%); water (3%) 3747 Lupasol SC (ICD# 3731) 10 Fluorolink 7004 40 40 (ICD3719, 2%), water (8%) 3748 Lupasol SC (ICD# 3731) 10 Fluorolink 7005 40 40 (ICD3730, 1%), water (9%) 3749 Lupasol SC (ICD# 3731) 15 Fluorolink 7005 35 44 (ICD3730, 1%), water (5%) 3750 Lupasol SC (ICD# 3731) 15 Fluorolink 7004 34 44 (ICD3719, 2%), water (5%) 3751 Lupasol G20 (ICD# 3733) 10 Fluorolink 7004 40 40 (ICD3719, 2%), water (8%) 3752 Lupasol G20 (ICD# 3733) 10 Fluorolink 7004 40 43 (ICD3719, 2%), water (5%) 3753 Lupasol G20 (ICD# 3733) 10 Fluorolink 7005 40 43 (ICD3730, 1%), water (6%) 3754 Lupasol G20(ICD# 3733) 15 Fluorolink 7005 36 43 (ICD3730, 1%), water (5%) 3755 Lupasol WF (ICD# 3732) 10 Fluorolink 7004 40 40 (ICD3719, 2%), water (8%) 3756 Lupasol WF (ICD# 3732) 10 Fluorolink 7004 40 35 (ICD3719, 2%), water (13%) 3757 Lupasol WF (ICD# 3732) 10 Fluorolink 7005 40 35 (ICD3730, 1%), water (14%) 3758 Lupasol WF (ICD# 3732) 15 Fluorolink 7005 44 35 (ICD3730, 1%), water (14%) 3759 Lupasol P (ICD# 3720) 15 Fluorolink 7005 44 36 (ICD3730, 1%), water (5%) 3760 Lupasol P (ICD# 3720) 19 Fluorolink 7005 44 36 (ICD3730, 1%), 3771 Lupasol P (ICD# 3720) 26 Fluorolink 7004 38 33 (ICD3719, 3%) 3772 Lupasol G20 (ICD# 3733) 26 Fluorolink 7005 38 33 (ICD3730, 3%) 3773 Lupasol G20 (ICD# 3733) 26 Fluorolink 7004 38 33 3774 Lupasol G20 (ICD# 3731) 26 Fluorolink 7004 38 33 (ICD3719, 3%) 3775 Lupasol SC (ICD# 3731) 26 Fluorolink 7005 38 33 (ICD3730, 3%); 3778 Lupasol WF (ICD# 3732) 26 Fluorolink 7005 38 33 (ICD3730, 3%) 3779 Lupasol WF (ICD# 3732) 26 Fluorolink 7004 38 33 (ICD3719, 3%) 3780 Lupasol FG (ICD# 3766) 26 Fluorolink 7005 38 33 (ICD3730, 3%) 3781 Lupasol FG (ICD# 3766) 26 Fluorolink 7004 38 33 (ICD3719, 3%) 3782 Lupasol FG (ICD# 3766) 13 and 13 Fluorolink 7004 38 33 Lupasol WF (ICD# 3732) (ICD3719, 1.5%) Fluorolink 7005 (ICD3730, 1.5%) 3786 Lupasol WF (ICD# 3732) 26 Fluorolink 7005 38 33 (ICD3730, 3%) 3787 Lupasol WE (ICD# 3732) 26 Fluorolink 7004 38 33 (ICD3719, 3%) 3790 Lupasol G20 (ICD# 3733) 26 Fluorolink 7004 38 33 (ICD3719, 3%) 3791 Lupasol WF (ICD# 3732) 26 Fluorolink 7005 38 33 (ICD3730, 3%) 3792 Lupasol FG (ICD# 3766) 26 Fluorolink 7005 38 33 (ICD3730, 3%) 3793 Lupasol P (ICD# 3720) 24 Fluorolink 7005 35 30 (ICD3730, 3%); water (9%) 3808 Dytek EP (ICD# 3863)  5 Fluorolink 7005 49 45 (ICD3730, 1%) 3809 Lupasol WF (ICD# 3732); 21 and 5 Fluorolink 7005 38 33 Dytek EP (ICD3730, 3%) 3810 Dytek EP (ICD# 3863)  5 Fluorolink 7004 49 45 (ICD3719, 3%) 3811 Lupasol FG (ICD# 3766) 21 and 5 Fluorolink 7005 38 33 Dytek EP (ICD3730, 3%) 3829 Lupasol P (ICD# 3720) 26 Fluorolink 7005 38 33 (ICD3730, 3%) 3830 Lupasol G20 (ICD# 3733) 26 Fluorolink 7005 38 33 (ICD3730, 3%) 3831 Lupasol SC (ICD# 3731) 26 Fluorolink 7005 38 33 (ICD3730, 3%) 3832 Lupasol WF (ICD# 3732) 26 Fluorolink 7005 38 33 (ICD3730, 3%) 3833 Lupasol FG (ICD# 3766) 26 Fluorolink 7004 38 33 (ICD3719, 3%) 3834 Lupasol FG (ICD# 3766); 13 and 13 Fluorolink 7004 38 33 Lupasol WF (ICD# 3732) (ICD3719, 1.5%) Fluorolink 7005 (ICD3730, 1.5%) 3835 Lupasol WF (ICD# 3732); 13 and 13 Fluorolink 7005 38 33 Lupasol FG (ICD# 3766) (ICD3730, 3%) 3836 Lupasol WF (ICD# 3732); 13 and 13 Fluorolink 7005 38 33 Lupasol G20 (lCD# 3733) (ICD3730, 3%) 3837 Lupasol WE (ICD# 3732); 13 and 13 Fluorolink 7005 38 33 Lupasol SC (ICD# 3731) (ICD3730, 3%) 3838 Lupasol WF (ICD# 3732); 13 and 13 Fluorolink 7005 38 33 Lupasol P (ICD# 3720) (ICD3730, 3%) 3839 Lupasol P (ICD# 3720); 13 and 13 Fluorolink 7005 38 33 Lupasol FG (ICD# 3766) (ICD3730, 3%) 3840 Lupasol P (ICD# 3720); 14 and 13 Fluorolink 7005 38 33 Lupasol G20 (ICD# 3733) (ICD3730, 3%) 3841 Lupasol P (ICD# 3720); 13 and 13 Fluorolink 7005 38 33 Lupasol SC (ICD# 3731) (ICD3730, 3%) 3842 Lupasol FG (ICD# 3766); 13 and 13 Fluorolink 7005 38 33 Lupasol SC (ICD# 3731) (ICD3730, 3%) 3843 Lupasol SC (ICD# 3731); 13 and 13 Fluorolink 7005 38 33 Lupasol G20 (ICD# 3733) (ICD3730, 3%) 3844 Lupasol G20 (ICD# 3733); 11 and 12 Fluorolink 7005 34 40 Lupasol FG (ICD# 3766) (ICD3730, 3%) 3853 Lupasol LU (ICD# 3852) 17 Fluorolink 7005 31 46 (ICD3730, 2%); water (4%) 3854 Lupasol LU (ICD# 3852) 23 Fluorolink 7005 35 40 (ICD3730, 3%) 3855 Lupasol LU (ICD# 3852) 20 Fluorolink 7004 38 35 (ICD3719, 1%); water (4%) 3856 Lupasol LU (ICD# 3852) 25 Fluorolink 7004 38 35 (ICD3719, 2%) 3857 Lupasol LU (ICD# 3852 13 and 13 Fluorolink 7004 38 33 Lupasol G20 (ICD# 3733) (ICD3730, 3%) 3858 Lupasol LU (ICD# 3852 13 and 13 Fluorolink 7005 38 33 Lupasol WF (ICD# 3732) (ICD3730, 3%) 3859 Lupasol LU (ICD# 3852 11 and 12 Fluorolink 7005 34 41 Lupasol SC (ICD# 3731) (ICD3730, 3%) 3860 Lupasol LU (ICD# 3852 12 and 12 Fluorolink 7005 35 38 Lupasol P (ICD# 3720) (ICD3730, 3%) 3861 Lupasol LU (ICD# 3852 12 and 12 Fluorolink 7005 36 37 Lupasol FG (ICD# 3766) (ICD3730, 3%) 3871 PAA-HCL-3L (ICD#3867) 23 Fluorolink 7004 34 41 (ICD3719, 3%) 3872 PAA-HCL-3L (ICD#3867) 26 Fluorolink 7005 38 33 (ICD3730, 3%) 3873 PAA-10C (ICD#3868) 19 Fluorolink 7004 28 52 (ICD3719, 1%) 3874 PAA-10C (ICD#3868) 18 Fluorolink 7005 25 55 (ICD3730, 2%) 3875 PAA-HCL-3L (ICD#3867) and 12 and 12 Fluorolink 7005 34 40 PAA-10C (ICD#3868) (ICD3730, 3%) 3884 Lupasol WF (ICD# 3732 13 and 13 Fluorolink 7005 38 33 Lupasol G20 (ICD# 3733) (ICD3730, 3%) 3885 Lupasol WF (ICD# 3732 13 and 13 Fluorolink 7005 38 33 Lupasol SC (ICD# 3733) (ICD3730, 3%) 3886 Lupasol P (ICD# 3732 13 and 13 Fluorolink 7005 38 33 Lupasol FG (ICD# 3733) (ICD3730, 3%) 3887 Lupasol P (ICD# 3732 14 and 13 Fluorolink 7005 38 33 Lupasol G20 (ICD# 3733) (ICD3730, 3%) 3900 Lupasol P (ICD# 3732 13 and 13 Fluorolink 7005 38 33 Lupasol SC (ICD# 3733) (ICD3730, 3%) 3901 Lupasol FG (ICD# 3732 13 and 13 Fluorolink 7005 38 33 Lupasol SC (ICD# 3733) (ICD3730, 3%) 3902 Lupasol SC (ICD# 3732 13 and 13 Fluorolink 7005 38 33 Lupasol G20 (ICD# 3733) (ICD3730, 3%) 3903 Lupasol G20 (ICD# 3732 11 and 12 Fluorolink 7005 34 40 Lupasol FG (ICD# 3733) (ICD3730, 3%) 3970 Lupasol WF (ICD# 3732) 26 Fluorolink 7004 38 33 (ICD3719 3%) 3971 Lupasol LU 321 (ICD# 3852) 25 Fluorolink 7004 38 35 (ICD3719, 2%) 3972 Lupasol LU 321 (ICD# 3852) 23 Fluorolink 7005 35 40 (ICD3730, 3%) 3994 Lupasol WF (ICD# 3732); 13 and 13 Fluorolink 7005 38 33 Lupasol P (ICD# 3720) (ICD3730, 3%) 3997 PAA-HCL-3L (ICD#3867) 23 Fluorolink 7004 38 33 (ICD3719, 3%) 3998 PAA-HCL-3L (ICD#3867) 26 Fluorolink 7005 37 34 (ICD3730, 3%) 3999 PAA-10C (ICD#3868) 19 Fluorolink 7005 28 52 (ICD3719, 1%) 4000 PAA-10C (ICD#3868) 18 Fluorolonk 7005 25 55 (ICD3730, 2%) 4020 Lupasol P (ICD# 3720); 14 and 13 Fluorolink 7005 38 33 Lupasol G20 (ICD# 3733) (ICD3730, 1.5%); Fluorolink 7004 (ICD3719, 1.5%) 4021 Lupasol P (ICD# 3720); 13 and 13 Fluorolink 7005 38 33 Lupasol WF (ICD# 3732) (ICD3730, 3%) 4022 Lupasol WF (IDC# 3732); 13 and 13 Fluorolink 7005 38 33 Lupasol FG (ICD# 3766) (ICD3730, 3%) 4029 Lupasol P (ICD# 3720) 13 and 13 Fluorolink 7005 38 33 Lupasol FG (ICD# 3766) (ICD3730, 1.5%); Fluorolink 7004 (ICD3719, 1.5%) 4032 Lupasol G20 (ICD# 3733) 13 Fluorolink 7005 44 42 (ICD3730, 2%) 4033 Lupasol G20 (ICD# 3733)  6 Fluorolink 7005 47 46 (ICD3730, 1%) 4034 Lupasol WF (ICD# 3732) 13 Fluorolink 7005 44 42 (ICD3730, 2%) 4035 Lupasol WF (ICD# 3732)  6 Fluorolink 7005 47 46 (ICD3730, 1%) 4036 Lupasol G20 (ICD# 3733) 14 Fluorolink 7004 43 41 (ICD3719, 2%) 4037 Lupasol G20 (ICD# 3733)  7 Fluorolink 7004 47 45 (ICD3719, 1%) 4038 Lupasol FG (ICD# 3766) 13 Fluorolink 7004 44 42 (ICD3719, 2%) 4039 Lupasol FG (ICD# 3766)  7 Fluorolink 7004 47 46 (ICD3719, 1%) 4040 Lupasol FG (ICD# 3766) 13 Fluorolink 7005 44 41 (ICD3730, 2%) 4041 Lupasol FG (ICD# 3766)  7 Fluorolink 7005 47 46 (ICD3730, 1%) 4042 Lupasol FG (ICD# 3766) 7 and 7 Fluorolink 7005 44 42 Lupasol WF (ICD# 3732) (ICD3730, 1%); Fluorolink 7004 (ICD3719, 1%) 4043 Lupasol FG (ICD# 3766) 3 and 3 Fluorolink 7005 49 47 Lupasol WF (ICD# 3732) (ICD3730, 0.5%); Fluorolink 7004 (ICD3719, 0.5%) 4044 Lupasol P (ICD# 3720); 13 Fluorolink 7005 45 41 (ICD3730, 1.5%) 4045 Lupasol P (ICD# 3720);  6 Fluorolink 7005 48 45 (ICD3730, 1%) 4046 Lupasol WF (ICD# 3732); 15 Fluorolink 7004 51 33 (ICD3719, 2%) 4047 Lupasol P (ICD# 3720); 14 Fluorolink 7004 48 36 (ICD3719, 2%) 4048 Lupasol WF (ICD# 3732);  7 Fluorolink 7004 50 41 (ICD3719, 1%) 4049 Lupasol P (ICD# 3720);  7 Fluorolink 7004 49 43 (ICD3719, 1%) 4050 Lupasol P (ICD# 3720) 13 and 13 Fluorolink 7005 38 33 Lupasol WF (ICD# 3732) (ICD3730, 1.5%); Fluorolink 7004 (ICD3719, 1.5%) 4051 Lupasol G20 (ICD# 3733) 13 and 13 Fluorolink 7005 38 33 Lupasol FG (ICD# 3766) (ICD3719, 1.5%); Fluorolink 7004 (ICD3719, 1.5%) 4052 Lupasol G20 (ICD# 3733) 13 and 13 Fluorolink 7005 38 33 Lupasol WF (ICD# 3732) (ICD3730, 1.5%); Fluorolink 7004 (ICD3719, 1.5%) Abbreviations for Table 1: PTFE: poly(tetrafluoroethylene) available as F5A powder from Ausimont, Morristown, NJ. PFPE: perfluoropolyether available as FOMBLIM ™ Y25 oil from Ausimont, Morristown, NJ. LCD 3719 Fluorolink 7004, available from Ausimont USA, Inc.; 1, Propene, 1,1,2,3,3,3- hexafluoro-, telomers with chlorotrifluoroethene, oxidized, reduced, ethyl ester, hydrolyzed, CAS # 220182-27-4. LCD 3720 Lupasol P, available from BASE Corp., a 50:50 wt % mixture of water and aziridine, homopolymer, CAS # 9002-98-6. LCD 3730 Fluorolink 7005, available from Ausimont USA, Inc.; a perfluoropolyether derivative (PFPE-CONH—(CH₂)₃—(OCH₂CH₃)₁₈—CH₃) from Ausimont, CAS # not assigned. ICD2853 Light PFPE Surfactant, Dupont, Wilmington, DE ICD3731 Lupasol SC 61B, available from BASE Corp., hydroxyethylated polyethylenimine, Product ID # NLE 555415. ICD3732 Lupasol WF (water free), available from BASE Corp., polyethylenimine, (CH₂—CH₂—NH—)_(x) Product ID # NLE 187702, CAS # 9002-98-6. ICD3733 Lupasol G20 water free, available from BASE Corp., polyethylenimine, Product ID # NLE 555415, CAS # 25987-06-8. ICD3852 Lupasol LU 321, available from BASE Corp., a 15:80:5 wt % mixture of formamide polymer (Product ID # NLE 073991) water, and sodium formate. ICD3863 Dytek EP, 1 ,3-pentanediamine, CAS # 589-37-7. ICD3766 Lupasol FG, available from BASE Corp., ethylenediamine-ethylenimine copolymer, (C₂H₈N₂.C₂H₅N)_(x) Product # NGS 971991, CAS # 25987-06-8. ICD3867 PAA-HCL-3L, 50.4 wt % aqueous solution of homopolymer of 2-propen-1-amine hydrochloride, CAS # 71550-12-4. ICD3868 PAA-10C, 10.3 wt % aqueous solution of homopolymer of 2-propen-1-amine, CAS # 30551-89-4. ICD3604 Diethanolamine modified (DEAM). Cross-linked polystyrene/divinylbenzene copolymer modified with 1.2 mmol/g diethanolamine. ICD3605 Diethanolamine modified (DEAM). Cross-linked polystyrene/divinylbenzene copolymer modified with 1.5 mmol/g diethanolamine. ICD 3606 Diethanolamine modified (DEAM). Cross-linked polystyrene/divinylbenzene copolymer modified with 1.0 mmol/g diethanolamine.

DEAM Structure (J. H. Hartley, and T. D. James, Tetrahedron Lett. 1999, 40, 2597-2600).

[0034] Examples of polyalkenimines are the polyethylenimines. These materials are available from BASF Corporation (4330 Chesapeake Dr., Charlotte, N.C.) under the trade name Lupasols.™ Lupasols (polyethylenimines, PEI) are multi-functional branched or spherical non-toxic cationic and neutral polymers. They are synthesized by the ring-opening polymerization of aziridine (ethylenimine). Depending on polymerization conditions, Lupasols contain various ratios of primary, secondary, and tertiary amines along the polymer backbone. Molecular weights also range from 800 to 2,000,000.

[0035] Polyethylenimines are synthesized from the ring opening polymerization of the nitrogen homologue of ethylene oxide. The resulting product is a highly branched, spherical polymer, which is easily protonated to form the most highly charged cationic polymer. As a result of their spherical shape and high cationic charge density, polyethylenimines are able to strongly bind onto anionic and polar surfaces. In addition, non-protonated amino groups are available to form hydrogen bonds or undergo further chemical reactions. Examples are given below:

[0036] The percent values assigned to the above listed components of the example skin protectant formulations in Table 1 are given for example only. These values may be adjusted up or down and still embody the spirit of the invention if the herein described qualities of efficacy and composition of the present invention are met.

[0037] All active moieties listed above are useful for both liquid and vapor challenges. The amount of each varies with each formulation. The object is to optimize the quantity of active moiety in the base cream without losing the barrier properties of the base cream. The amount of active moiety can vary from about 1-30%. The amount of perfluorinated polyether oil can vary from about 30 to 60%. The amount of poly(tetrafluoroethylene) can vary from about 20 to 50%. One criterion for selection of the active materials is increased efficacy against HD and/or GD vapor. Most the listed formulations have significantly (P=0.05) increased protection compared to SERPACWA (ICD 3004) in the penetration cell model against HD and/or GD and are listed in the Results sections.

[0038] The polyalkenimines must also be incorporated into the TSP matrix without degradation of the barrier properties. These materials were incorporated into the cream either as solids or aqueous suspensions. Typically they are dispersed into the perfluorinated oil followed by sequential addition of the appropriate amount of F5A poly(tetrafluoroethylene). The TSP can contain individual polyalkenimines or mixtures of two or more polyalkenimines.

[0039] SERPACWA (ICD3004) consists of fine particles of poly(tetrafluoroethylene) resin dispersed in perfluorinated polyether oil. The excellent barrier properties of this high molecular weight polymer formulation are related to the low solubility of most materials in it. Only highly fluorinated solvents like Freon® have been observed to show appreciable solubility. This aprotic non-polar polymer mixture provides a unique medium for active moieties of the invention. Reaction mechanisms that do not involve charged transition states should be favored in this chemical environment.

[0040] Base creams formed from about 20-50% fine particulates of certain poly(tetrafluoroethylene) PTFE resins dispersed in perfluorinated polyether oils (PFPE) having viscosities from about 20 cSt to about 500 cSt afford good protection against chemical warfare agents such as HD, Lewisite (L), sulfur mustard/Lewisite mixtures (HL), pinacolyl methylphosphonofluoridate (soman or GD), thickened soman (TGD) and O-ethyl S-(2-diisopropylaminoethyl)methylphosphonothiolate (VX). PTFE and PFPE are available commercially from Ausimont (Morristown, N.J.) and Dupont (Wilmington, Del.).

[0041] The base creams used in the invention are suspensions of 20-50% finely divided PTFE having a surface area below about 6 m²/g in a perfluorinated polyether base oil prepared from poly(perfluoropropylene oxide), which has a viscosity between about 20 and about 500 cSt. More preferred compositions comprise from about 20% to about 50% of finely divided PTFE having an average particle size from about 0.1 μm to about 10 μm and a surface area below about 4 m²/g in a perfluorinated polyether base oil from 30% to 60% having a viscosity between about 20 and about 500 cSt.

[0042] Suitable perfluorinated polyether oils are Fomblin® HC- and Y-oils (Ausimont) and Krytox® oils (Dupont). The Fomblin® oils are mixtures of linear polymers based on poly(perfluoropropylene oxide) having the following chain structure: CF₃-[(OCF(CF₃)CF₂)_(n)-(OCF₂CF₂)_(m)]OCF₃. The Krytox® oils are mixtures of linear polymers also based on perfluoropropylene oxide and have the chemical structure F-[(CF(CF₃)CF₂O)]_(m)CF₂CF₃. Fomblin® Z oils having the formula: CF₃-[(OCF₂CF₂)_(n)-(OCF₂)_(m)]-OCF₃, may also be useful in the practice of the invention. The indices n and m indicate the average number of repeating polymeric subunits in the oil molecules. The oils may have a viscosity of about 20 cSt to about 500 cSt or more. The creams were generally prepared according to U.S. Pat. No. 5,607,979, incorporated herein in its entirety.

[0043] Other additives to the base cream are water and surfactant and other chemicals necessary to maintain activity. The surfactant facilitates the mixing of the water with the base cream. Examples of typical surfactants are perfluoropolyalkylether (Krytox® CAS #60164-51-4 from Dupont), Fluorolink® 7004 (1,Propene, 1,1,2,3,3,3-hexafluoro-, telomers with chlorotrifluoroethene, oxidized, reduced, ethyl ester, hydrolyzed, CAS #220182-27-4 from Ausimont), and Fluorolink® 7005 (a perfluoropolyether derivative from Ausimont, CAS # not assigned). Additional materials may also be incorporated as long as they do not reduce effectiveness of the topical protectant, such as stabilizers, camouflage paints, and sunscreens.

[0044] A further understanding of the composition of the topical protectant of the invention can be obtained by reference to certain specific example formulations set forth in Table 1. These examples are provided herein for purposes of illustration only and are not intended to be limiting. Many active moieties require the presence of water as a reagent for the hydrolysis of HD and GD. The active moieties that react by a hydrolysis mechanism require the presence of water. When the topical protectant is applied to the skin of a user, moisture in the form of perspiration may also aid in the hydrolysis of HD and GD. The addition of perfluorinated polyether surfactants to the base cream facilitates the addition of water.

[0045] Temperature and mixing sheer should be monitored to maintain the base cream at the desired consistency and quality. The active TSPs are typically prepared at ambient temperature using mechanical mixing or at controlled temperatures using either a single screw or dual screw commercial extruder (Haake® Rheomix extruder). Mixing times of 10-20 minutes are usually sufficient for dispersal of polyalkenimines into the PFPE/PTFE matrix. A typical procedure for the preparation of an active TSP with a polyalkenimine is presented below:

[0046] In a polypropylene container is added the appropriate amount of polyalkenimine (1-30% by weight) and Y25 (30-60% by weight) perfluorinated oil. The suspension is mixed with a mechanical stirrer at ambient temperature for 5 to 15 minutes or with a magnetic stirrer for 10 to 20 hours. To the suspension is added F5A poly(tetrafluoroethylene) in three portions with vigorous mechanical stirring for 5 to 10 minutes between each addition. After final addition the container is tightly capped and sealed with Parafilm®. Commercial extruders or other high-shear mixing techniques can improve the quality of the final product.

[0047] Multilayer Approach

[0048] Although an active TSP can be applied directly to the skin, the application of a powder (or liquid) that is a polyalkenimine sprinkled on the skin, or an active moiety in a base cream wherein the cream is spread on the skin, a multilayering approach can also be used. The multilayer approach would be to use the active TSP as the first layer and a solid active moiety powder (or liquid or other reactive matrix) as the second layer. The second layer would be a thin coating of the active moiety sprinkled over the active TSP cream. This approach would provide a concentrated decontamination material at the surface of the barrier cream, which would accelerate the neutralization process of CWAs coming in contact with the surface. Alternatively, the first layer can be a thin coating of the active moiety followed by a second layer of the active TSP.

[0049] Testing

[0050] Evaluation of formulations was conducted with a decision tree network (DTN) that describes the path that active TSPs follow during evaluation (FIG. 1).

[0051] The DTN is divided into two pathways: one for vesicants and the other for nerve agents. Within these pathways there are three blocks each with a decision point. The first block consists of a series of three mechanical (in vitro) modules used to determine the initial efficacy of candidate formulations and to eliminate non-effective candidates before animal testing, the second block consists of in vivo modules and the third block consists of an advanced animal module to determine the influence of time, water, sweat, and interactions with other products.

[0052] The M8 paper test is used to evaluate the barrier resistance of liquid CWA challenges, including HD, pinacolyl methylphosphonofluoridate (soman, GD), and O-ethyl S-(2-diisopropylaminoethyl) methylphosphonothioate (VX). In this test a 0.15 mm layer of active TSP is placed over a well-defined area of M8 chemical detection paper and challenged with an 8 μl droplet of CWA. When agent penetrates the active TSP barrier and reaches the M8 paper, a colored spot develops on the paper. The test assemblies are observed for 6 hr and the breakthrough time is reported for each sample. A total of nine replicates are run for each test, and a standard reference compound is included each day for quality control.

[0053] The penetration cell test is used to evaluate the barrier properties against both liquid and vapor CWA challenges (Braue, E. H. Jr. Journal of Applied Toxicology, 1999, 19(S), S47-S53). In this test the lower half of a Reifenrath diffusion cell (Reifenrath Consulting and Research, Richmond, Calif.) is used. A 0.15 mm thick layer of active TSP is supported by nitrocellulose paper on top of the cell. The active TSP layer is challenged with a 10-μl liquid droplet of HD or an 8 μl droplet of GD, or a saturated vapor cup of HD or GD. Breakthrough of CWA into the lower chamber of the diffusion cell is monitored using a miniature continuous air monitoring system (MINICAMS, CMS Research, Birmingham, Ala.). This system has been automated to allow continuous monitoring of five cells in a 40-min cycle. The test runs for 20 hr and the accumulated amounts of agent that break through the active TSP barrier are calculated. From these data, we obtained two values: the cumulative amount of CWA that penetrates through the active TSP, and the time at which a “breakthrough” occurs. We defined “breakthrough” values at the minimum amount of HD (1000 ng) and GD (1000 ng) that results in a physiological response. Minimal amount of HD for vesication is 1000 ng. See F. R. Sidell, J. S. Urbanetti, W. J. Smith, and C. G. Hurst in Textbook of Military Medicine, Medical Aspects of Chemical and Biological Warfare, edited by F. R. Sidell, E. T. Takafuji, and D. R. Franz (Office of the Surgeon General at TMM Publications, Washington, D. C. 1997) p 201. The LD₅₀ for soman (GD) is 350 mg/70 kg man. See F. R. Sidell in Textbook of Military Medicine, Medical Aspects of Chemical and Biological Warfare, edited by F. R. Sidell, E. T. Takafuji, and D. R. Franz (Office of the Surgeon General at TMM Publications, Washington, D. C. 1997) p 141. These two values allow us to rank the active TSP formulations and to select the appropriate component for advanced development.

[0054] The proof-of-neutralization test is used to verify that active TSP formulations actually neutralize CWAs into less toxic materials. This test uses the headspace solid phase microextraction (HS-SPME) technique for the collection of CWAs. Samples collected on the extraction filament are analyzed by gas chromatography/mass spectroscopy. 100 mg of active TSP formulation are challenged with 0.1 μl of neat CWA (HD, GD, or VX) in a small vial. The headspace above the mixture is sampled periodically to determine the amount of CWA remaining in the flask. Efficacy is determined by the % loss of CWA. Other analytical techniques such as Nuclear Magnetic Resonance (NMR) and Fourier-Transform Infrared Spectrometry (FTIR) have also been used in this module.

[0055] Formulations that pass this initial set of screens are moved into the second phase of testing using animal models. The weakling pig test for HD vapor evaluates a 0.15 mm thick layer of active TSP spread on the depilated dorsa. The standard saturated vapor cup is used for a 30 min challenge. The effectiveness of the active TSP is determined by measuring the degree of erythema that developed on the skin exposure site. Erythema is measured objectively using a reflectance calorimeter (see Braue, E. H. Jr. Journal of Applied Toxicology, 1999, 19(S), S47-S53).

[0056] The rabbit lesion area ratio (LAR) test is used to evaluate a challenge by HD liquid. In this test, a 0.15 mm layer of active TSP spread on the clipped dorsa is challenged with 1.0 μl of liquid HD spread by a 12 mm disk. The effectiveness of the active TSP is determined by measuring the lesion areas of protected and non-protected sites.

[0057] The rabbit lethality test is used to evaluate a challenge by GD vapor. In this test, a 0.15 mm layer of active TSP spread on the clipped dorsa is challenged with two vapor cups (7 cm² each) containing 28 mg GD per kg of body weight. The liquid GD is saturated onto filter paper fitted into the top of the cap so that liquid can not run down. The caps are left in place for 4 hours. After the exposure period the caps are removed and the exposure sites decontaminated. This exposure dose is lethal to all animals not protected with active TSP. The effectiveness of the active TSP is determined by lethality 1, 2, 3, 4 and 24 hr following exposure.

[0058] The guinea pig lethality test is performed by applying a 0.15 mm thick layer of active TSP on the clipped dorsa of guinea pig followed by a fixed dose of GD, TGD or VX. The effectiveness of the active TSP is determined by lethality 1, 2, 3, 4 and 24 hr following exposure.

[0059] Candidate formulations that pass the in vivo test modules move into advanced animal testing. These tests are similar to the initial animal tests with the addition of stresses for wear-time and washing with a simulated sweat solution. Interactions with other products that a warfighter might use are also evaluated. These products include camouflage paints, sunscreens and insecticides.

[0060] Results

[0061] The polyalkenimines are effective active moieties reducing the amount of HD vapor by >99% relative to the TSP alone. Although the exact mechanisms for HD neutralization are not clear, they may react by hydrolysis, direct alkylation of the polyalkenimine, or dehydrohalogenation (Scheme 1).

[0062] Against GD vapor the polyalkenimines reduced the amount of GD by >99% compared to TSP alone. In this case, it is likely that the polyalkenimines are active as nucleophiles or else accelerate hydrolysis through general base catalysis (Scheme 2).

[0063] Many of the listed active TSPs contain water, and the in model reactions with a GD simulant, diisopropylfluorophosphate, (DFP), the products have FT-IR and ³¹p NMR spectra that are consistent with hydrolysis. Another possibility is that adventitious adsorbed water in formulations that did not have water added directly act as a reagent for this hydrolysis.

[0064] The increase in protection for the polyalkenimines was impressive against GD vapor as seen by the decrease in total ng that breakthrough the active TSP as compared to SERPACWA (ICD3004) (FIG. 6). FIG. 6 shows a total amount of GD vapor that penetrates a 0.15 mm thick aTSP barrier in 20 hr. ICD3004 (SERPACWA) is off scale with a value of 6672 ng.

[0065] Many of the formulations reduce the amount of GD vapor by >99%. Most samples display significantly (P=0.05) increased protection compared to SERPACWA (ICD 3004) in the penetration cell model against GD vapor.

[0066] The increase in protection for aTSPs formulations containing polyalkenimines was also remarkable against HD vapor as demonstrated by the decrease in total ng that break through the active TSP in 20 hours as compared to SERPACWA (ICD3004) (FIG. 7).

[0067] As clearly seen in FIG. 7, most of the formulations containing polyalkenimines have shown outstanding protection against HD vapor in the penetration cell model. Many offer significantly better (P=0.05) protection against HD vapor compared to SERPACWA (ICD 3004).

[0068] To roughly determine the resistance of aTSPs containing polyalkenimines, the M8 paper test was performed. All formulations tested against HD liquid proved impervious over the duration of the test (360 min) but showed variable resistance against GD liquid (FIG. 8).

[0069] Limited penetration cell testing has also been accomplished against HD and GD liquid. In this module, the aforementioned a TSPs performed well against GD but were ineffective against HD (FIG. 9).

[0070] In addition to the penetration cell model, certain active TSP containing polyalkenimines were tested in the headspace solid phase micro-extraction gas chromatography/mass spectrometry (HS-SPME/GC-MS) test against HD. In this module significant efficacy was seen against HD, GD, and VX (FIG. 10). For FIG. 10, evaluation of active TSPs containing polyalkenimines against HD, GD, and VX liquid using headspace solid phase micro-extraction gas chromatography/mass spectrometry (HS-SPME-GC/MS). Percent of Control is the ratio (expressed as %) of the headspace concentration of the CWA determined for each formulation divided by the headspace concentration determined for SERPACWA.

[0071] Possible neutralization pathways of these amines, polyalkenimines, and derivatives were probed using NMR with diisopropylfluorophosphate (DFP) as a GD simulant and CEES as an HD simulant. To determine the relative activity of different polyalkenimines towards organophosphates, the first experiments monitored the hydrolysis of DFP in deuterated water (D₂O). ³¹P NMR spectra were obtained displaying both the native DFP (d, −11.6 ppm) and it hydrolysis product (s, −2.5 ppm). These spectra were obtained at regular intervals over 14 hours (FIG. 2). The extent of hydrolysis was determined by taking the ratio of the integrations of the signals for DFP and its hydrolysis product. By plotting the percent hydrolysis versus time, we were able to perform an initial ranking of the polyalkenimines (FIG. 11).

[0072] To determine the possible reaction pathways for the neutralization of HD by polyalkenimines, we performed a series of experiments measuring the degree of hydrolysis in an HD simulant, 2-chloroethylethylsulfide (CEES). First, we obtained the ¹H NMR spectra of CEES in d₆-DMSO (FIG. 3). Next, we added 100 equivalents of D₂O to the NMR tube and obtained ¹H spectra after 18 hours giving us a baseline extent of hydrolysis (FIG. 4). Finally, we prepared a standard solution of CEES in d₆-DMSO and added a 2.5 wt % solution of polyalkenimine in D₂O (still 100 eq D₂O). Peak at ˜4.1 ppm is from D₂O, broad peak from 2.5 to 3.0 ppm is from the Lupasol WF (FIG. 5). By comparing the spectra of CEES, CEES/D₂O and CEES/polyalkenimine/D₂O, it is evident that significant hydrolysis occurs by the disappearance of CEES signals (3.75, 2.85, 2.55, 1.17 ppm).

[0073] Most of the active TSPs containing polyalkenimines also show excellent efficacy in the weanling pig HD vapor model (Table 2). The best active TSPs containing polyalkenimines almost completely eliminated erythema in this test. TABLE 2 Weanling pig test results for HD vapor. Erythema as percentage of positive control (% of PC). Positive control has no aTSP applied. SEM is the standard error of the mean. Formulations pass the test if they offer significantly (p < 0.05) better protection than un-protected skin. Formulations Formulations Passing Test Failing Test ICD No. % of PC SEM ICD No. % of PC SEM 3470 56.4 10.5 3004 102 1.8 3718 −9.6 17.5 3471 61.5 11.9 3742 39 10.6 3630 110.6 5.9 3743 41.7 10 3631 103.5 5.4 3771 25.1 7.6 3724 100.4 3.1 3772 30.8 7.2 3725 86.3 7.1 3773 16.3 3.3 3728 93.9 9.5 3778 29 3.2 3729 95.7 7.3 3779 43.3 8.5 3744 117.3 8.2 3780 28.1 3.8 3745 117.2 10.2 3781 39.4 7.3 3809 87.9 8.6 3782 16 3.8 3831 82.7 5.9 3829 61.7 9.4 3900 80.5 10.4 3830 38.9 7.1 4033 104.3 13 3832 26.1 5.7 4037 90.9 12.9 3833 15.7 7.3 4039 91.5 4 3834 11.6 5.9 4040 77.4 11 3884 23.5 10.7 4041 114.7 15.3 3885 70.7 13.1 4043 90.6 6.5 3886 46.9 11.8 3887 48.3 9.1 3901 73.6 7.4 3902 68.5 5.3 3903 50.5 9.5 4020 12.4 11.6 4021 35.9 16.7 4022 43.4 13.5 4029 25.5 5 4032 54.6 7.7 4034 59.7 7.1 4036 46.3 7.6 4038 55.5 6.4 4042 59.6 10.9 4044 69.6 7.7 4046 13.2 4.6 4047 44.3 6.1 4048 66.1 7.2 4049 82.8 6.2 4050 13.4 5.4 4051 18.6 7.9 4052 10.2 8

[0074] All of the active TSPs containing polyalkenimines tested against HD liquid in the Lesion Area Ratio (LAR) test showed significant (p<0.05) protection compared to un-protected skin (FIG. 12). Lesion Area Ratio is the measure of the protection given by the aTSP and compares the lesion size between sites protected by aTSP with sites not protected by aTSP. Several of the formulations also demonstrate significantly improved protection compared to SERPACWA (ICD3004).

[0075] A limited number of the active TSPs containing polyalkenimines were also tested in the rabbit lethality test for GD vapor. Many show excellent efficacy. Lethality at 1, 2, 3, 4 and 24 hours post exposure from 2 vapor caps each containing 28 mg GD/kg for 4 hrs. (FIG. 13).

[0076] A limited number of the active TSPs containing polyalkenimines were also tested in the rabbit lethality test for VX liquid. Lethality at 1, 2, 3, 4 and 24 hr. post exposure to 0.5 mg VX/kg for 4 hrs. All were significantly (p <0.05) better than no protection (FIG. 14).

[0077] Having now fully described the invention, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the invention as set forth herein. 

What is claimed is:
 1. A topical skin protectant formulation for neutralizing chemical warfare agents into less toxic products comprising: (a) a barrier base cream, said barrier base cream comprising poly(tetrafluoroethylene) resins dispersed in perfluorinated polyether oils; and (b) one or more active moieties comprising amines, polyalkenimines and its derivatives.
 2. The topical protectant formulation of claim 1, wherein said amines, polyalkenimines and its derivatives are selected from the group consisting of: (a) Lupasol P (b) Lupasol WF (c) Lupasol G20 (d) Lupasol SC, (e) Lupasol G20, (f) Lupasol LU, (g) Dytek EP, (h) homopolymer of 2-propen-1-amine hydrochloride (PAA-HCL-3L), (i) homopolymer of 2-propen-1-amine (PAA-10C), and (j) diethanolamine modified.
 3. The topical skin protectant formulation of claim 1, further comprising one or more additives.
 4. The topical skin protectant formulation of claim 3, wherein said additives comprise one or more of water, surfactants such as Fluorolink 7004, Fluorolink 7005 and perfluoropolyether light surfactant, stabilizers, camouflage paints, and sunscreens.
 5. A topical skin protectant formulation for neutralizing chemical warfare agents into less toxic products comprising: (a) a barrier base cream, said barrier base cream comprising poly(tetrafluoroethylene) resins dispersed in perfluorinated polyether oils; (b) one or more active moieties comprising: (a) Lupasol P (b) Lupasol WF (c) Lupasol G20 (d) Lupasol SC, (e) Lupasol G20, (f) Lupasol LU, (g) Dytek EP, (h) homopolymer of 2-propen-1-amine hydrochloride (PAA-HCL-3L), (i) homopolymer of 2-propen-1-amine (PAA-10C), and (j) diethanolamine modified. (c) one or more additives.
 6. The topical skin protectant formulation of claim 5, wherein said additives comprise one or more of water, surfactant such as Fluorolink 7004, Fluorolink 7005, and perfluoropolyether light surfactant, stabilizers, camouflage paints, and sunscreens.
 7. A topical skin protectant system comprising: b) a topical skin protectant formulation for neutralizing chemical warfare agents into less toxic products comprising a barrier cream and one or more active moieties, said active moieties comprising amines, polyalkenimines and its derivatives and c) a second formulation for applying a thin solid or liquid active moiety powder or liquid on top or below said topical skin protectant formulation comprising one or more amines, polyalkenimines ad its derivatives.
 8. The topical skin protectant system of claim 7, wherein said one or more active moieties in the topical skin protectant formulation and in the solid or liquid active moiety powder or liquid is: (a) Lupasol P (b) Lupasol WF (c) Lupasol G20 (d) Lupasol SC, (e) Lupasol G20, (f) Lupasol LU, (g) Dytek EP, (h) homopolymer of 2-propen-1-amine hydrochloride (PAA-HCL-3L), (i) homopolymer of 2-propen-1-amine (PAA-10C), and (j) diethanolamine modified.
 9. A method of protecting a user against chemical warfare agents comprising: applying a topical skin protectant formulation for neutralizing chemical warfare agents into less toxic products comprising: (a) a barrier cream and (b) one or more active moieties, said one or more active moieties comprising amines, polyalkenimines and its derivatives.
 10. A method of protecting a user against chemical warfare agents comprising: a) applying a first thin layer of solid or liquid active moiety powder or liquid comprising one or more amines, polyalkenimines and its derivatives; and b) applying a second layer of a topical skin protectant formulation for neutralizing chemical warfare agents into less toxic products comprising a barrier cream and one or more active moieties comprising one or more amines, polyalkenimines and its derivatives.
 11. The method of claim 10, wherein said one or more active moieties in the topical skin protectant formulation and in the solid or liquid active moiety powder or liquid is: (a) Lupasol P (b) Lupasol WF (c) Lupasol G20 (d) Lupasol SC, (e) Lupasol G20, (f) Lupasol LU, (g) Dytek EP, (h) homopolymer of 2-propen-1-amine hydrochloride (PAA-HCL-3L), (i) homopolymer of 2-propen-1-amine (PAA-10C), and (j) diethanolamine modified.
 12. A method of protecting a user against chemical warfare agents comprising: a) applying a first layer of a topical skin protectant formulation for neutralizing chemical warfare agents into less toxic products comprising a barrier cream and one or more active moieties, said one or more active moieties comprising one or more amines, polyalkenimines and its derivatives; and b) applying a thin layer of solid or liquid active moiety powder or liquid over the first layer, said solid or liquid active moiety powder comprising one or more amines, polyalkenimines and its derivatives.
 13. The method of claim 12, wherein said one or more active moieties in the topical skin protectant formulation and in the solid or liquid active moiety powder or liquid is: (a) Lupasol P (b) Lupasol WF (c) Lupasol G20 (d) Lupasol SC, (e) Lupasol G20, (f) Lupasol LU, (g) Dytek EP, (h) homopolymer of 2-propen-1-amine hydrochloride (PAA-HCL-3L), (i) homopolymer of 2-propen-1-amine (PAA-10C), and (j) diethanolamine modified.
 14. A method of making a topical skin protectant formulation comprising: mixing: a) one or more active moieties comprising amines, polyalkenimines and its derivatives, with b) a barrier cream comprising poly(tetrafluoroethylene) resins dispersed in perfluorinated polyether oils.
 15. The method of claim 14, wherein said amines, polyalkenimines and its derivatives are selected from the group consisting of: (a) Lupasol P (b) Lupasol WF (c) Lupasol G20 (d) Lupasol SC, (e) Lupasol G20, (f) Lupasol LU, (g) Dytek EP, (h) homopolymer of 2-propen-1-amine hydrochloride (PAA-HCL-3L), (i) homopolymer of 2-propen-1-amine (PAA-10C), and (j) diethanolamine modified.
 16. A topical skin protectant formulation of claim 2 comprising: a) about 10 wt % Lupasol P, and b) about 2 wt % Fluorolink 7004, and c) about 7 wt % water and d) about 48 wt % perfluoropolyether; and e) about 32 wt % poly(tetrafluoroethylene).
 17. A topical skin protectant formulation of claim 2 comprising: a) about 7 wt % Lupasol P, and b) about 3 wt % Fluorolink 7004, and c) about 10 wt % water and d) about 48 wt % perfluoropolyether; and e) about 32 wt % poly(tetrafluoroethylene).
 18. A topical skin protectant formulation of claim 2 comprising: a) about 20 wt % Lupasol P, and b) about 2 wt % Fluorolink 7004, and c) about 3 wt % water and d) about 60 wt % perfluoropolyether; and e) about 15 wt % poly(tetrafluoroethylene).
 19. A topical skin protectant formulation of claim 2 comprising: a. about 25 wt % Lupasol P, and b. about 2 wt % Fluorolink 7004, and c. about 7 wt % water and d. about 45 wt % perfluoropolyether; and e. about 21 wt % poly(tetrafluoroethylene).
 20. A topical skin protectant formulation of claim 2 comprising: a) about 25 wt % Lupasol P, and b) about 2 wt % Fluorolink 7004, and c) about 5 wt % water and d) about 43 wt % perfluoropolyether; and e) about 25 wt % poly(tetrafluoroethylene).
 21. A topical skin protectant formulation of claim 2 comprising: a) about 25 wt % Lupasol P, and b) about 2 wt % Fluorolink 7004, and c) about 3 wt % water and d) about 40 wt % perfluoropolyether; and e) about 30 wt % poly(tetrafluoroethylene).
 22. A topical skin protectant formulation of claim 2 comprising: a) about 25 wt % Lupasol P, and b) about 2 wt % Fluorolink 7004, and c) about 8 wt % water and d) about 35 wt % perfluoropolyether; and e) about 30 wt % poly(tetrafluoroethylene).
 23. A topical skin protectant formulation of claim 2 comprising: a) about 10 wt % Lupasol P, and b) about 10 wt % water, and c) about 55 wt % perfluoropolyether; and d) about 25 wt % poly(tetrafluoroethylene).
 24. A topical skin protectant formulation of claim 2 comprising: a) about 20 wt % Lupasol P, and b) about 40 wt % perfluoropolyether; and c) about 40 wt % poly(tetrafluoroethylene).
 25. A topical skin protectant formulation of claim 2 comprising: a. about 26 wt % Lupasol P, and b. about 3 wt % Fluorolink 7004, and c. about 38 wt % perfluoropolyether; and d. about 33 wt % poly(tetrafluoroethylene).
 26. A topical skin protectant formulation of claim 2 comprising: a) about 26 wt % Lupasol P, and b) about 3 wt % Fluorolink 7005, and c) about 38 wt % perfluoropolyether; and d) about 33 wt % poly(tetrafluoroethylene).
 27. A topical skin protectant formulation of claim 2 comprising: a) about 15 wt % Lupasol P, and b) about 1 wt % Fluorolink 7005, and c) about 44 wt % perfluoropolyether; and d) about 36 wt % poly(tetrafluoroethylene), and e) about 5 wt % water.
 28. A topical skin protectant formulation of claim 2 comprising: a) about 19 wt % Lupasol P, and b) about 1 wt % Fluorolink 7005, and c) about 44 wt % perfluoropolyether; and d) about 36 wt % poly(tetrafluoroethylene).
 29. A topical skin protectant formulation of claim 2 comprising: a) about 24 wt % Lupasol P, and b) about 3 wt % Fluorolink 7005, and c) about 35 wt % perfluoropolyether; and d) about 30 wt % poly(tetrafluoroethylene), and e) about 9 wt % water.
 30. A topical skin protectant formulation of claim 2 comprising: a) about 10 wt % Lupasol WF, and b) about 2 wt % Fluorolink 7004, and c) about 8 wt % water, and d) about 40 wt % perfluoropolyether; and e) about 40 wt % poly(tetrafluoroethylene).
 31. A topical skin protectant formulation of claim 2 comprising: a) about 10 wt % Lupasol WF, and b) about 2 wt % Fluorolink 7004, and c) about 13 wt % water, and d) about 40 wt % perfluoropolyether; and e) about 35 wt % poly(tetrafluoroethylene).
 32. A topical skin protectant formulation of claim 2 comprising: a. about 10 wt % Lupasol WF, and b. about 1 wt % Fluorolink 7005, and c. about 14 wt % water, and d. about 40 wt % perfluoropolyether; and e. about 35 wt % poly(tetrafluoroethylene).
 33. A topical skin protectant formulation of claim 2 comprising: a) about 15 wt % Lupasol WF, and b) about 1 wt % Fluorolink 7005, and c) about 5 wt % water, and d) about 44 wt % perfluoropolyether; and e) about 35 wt % poly(tetrafluoroethylene).
 34. A topical skin protectant formulation of claim 2 comprising: a) about 26 wt % Lupasol WF, and b) about 3 wt % Fluorolink 7005, and c) about 38 wt % perfluoropolyether; and d) about 33 wt % poly(tetrafluoroethylene).
 35. A topical skin protectant formulation of claim 2 comprising: a) about 26 wt % Lupasol WF, and b) about 3 wt % Fluorolink 7004, and c) about 38 wt % perfluoropolyether; and d) about 33 wt % poly(tetrafluoroethylene).
 36. A topical skin protectant formulation of claim 2 comprising: a) about 21 wt % Lupasol WF, and b) about 5 wt % Dytek EP, and c) about 3 wt % Fluorolink 7005, and d) about 38 wt % perfluoropolyether; and e) about 33 wt % poly(tetrafluoroethylene).
 37. A topical skin protectant formulation of claim 2 comprising: a) about 10 wt % Lupasol G20, and b) about 2 wt % Fluorolink 7004, and c) about 8 wt % water and d) about 40 wt % perfluoropolyether; and e) about 40 wt % poly(tetrafluoroethylene).
 38. A topical skin protectant formulation of claim 2 comprising: a) about 10 wt % Lupasol G20, and b) about 2 wt % Fluorolink 7004, and c) about 5 wt % water and d) about 40 wt % perfluoropolyether; and e) about 43 wt % poly(tetrafluoroethylene).
 39. A topical skin protectant formulation of claim 2 comprising: a) about 10 wt % Lupasol G20, and b) about 1 wt % Fluorolink 7005, and c) about 6 wt % water and d) about 40 wt % perfluoropolyether; and e) about 43 wt % poly(tetrafluoroethylene).
 40. A topical skin protectant formulation of claim 2 comprising: a) about 15 wt % Lupasol G20, and b) about 1 wt % Fluorolink 7005, and c) about 5 wt % water and d) about 36 wt % perfluoropolyether; and e) about 43 wt % poly(tetrafluoroethylene).
 41. A topical skin protectant formulation of claim 2 comprising: a) about 26 wt % Lupasol G20, and b) about 3 wt % Fluorolink 7005, and c) about 38 wt % perfluoropolyether; and d) about 33 wt % poly(tetrafluoroethylene).
 42. A topical skin protectant formulation of claim 2 comprising: a) about 26 wt % Lupasol G20, and b) about 3 wt % Fluorolink 7004, and c) about 38 wt % perfluoropolyether; and d) about 33 wt % poly(tetrafluoroethylene).
 43. A topical skin protectant formulation of claim 2 comprising: a) about 10 wt % Lupasol SC, and b) about 2 wt % Fluorolink 7004, and c) about 40 wt % perfluoropolyether; and d) about 45 wt % poly(tetrafluoroethylene), and e) about 3 wt % water.
 44. A topical skin protectant formulation of claim 2 comprising: a) about 10 wt % Lupasol SC, and b) about 2 wt % Fluorolink 7004, and c) about 8 wt % water and d) about 40 wt % perfluoropolyether; and e) about 40 wt % poly(tetrafluoroethylene).
 45. A topical skin protectant formulation of claim 2 comprising: a) about 10 wt % Lupasol SC, and b) about 1 wt % Fluorolink 7004, and c) about 9 wt % water and d) about 40 wt % perfluoropolyether; and e) about 40 wt % poly(tetrafluoroethylene).
 46. A topical skin protectant formulation of claim 2 comprising: a) about 15 wt % Lupasol SC, and b) about 1 wt % Fluorolink 7005, and c) about 5 wt % water and d) about 35 wt % perfluoropolyether; and e) about 44 wt % poly(tetrafluoroethylene).
 47. A topical skin protectant formulation of claim 2 comprising: a) about 15 wt % Lupasol SC, and b) about 2 wt % Fluorolink 7004, and c) about 5 wt % water and d) about 34 wt % perfluoropolyether; and e) about 44 wt % poly(tetrafluoroethylene).
 48. A topical skin protectant formulation of claim 2 comprising: a) about 26 wt % Lupasol SC, and b) about 3 wt % Fluorolink 7004, and c) about 38 wt % perfluoropolyether; and d) about 33 wt % poly(tetrafluoroethylene).
 49. A topical skin protectant formulation of claim 2 comprising: a. about 26 wt % Lupasol SC, and b. about 3 wt % Fluorolink 7005, and c. about 38 wt % perfluoropolyether; and d. about 33 wt % poly(tetrafluoroethylene).
 50. A topical skin protectant formulation of claim 2 comprising: a) about 26 wt % Lupasol FG, and b) about 3 wt % Fluorolink 7005, and c) about 38 wt % perfluoropolyether; and d) about 33 wt % poly(tetrafluoroethylene).
 51. A topical skin protectant formulation of claim 2 comprising: a) about 26 wt % Lupasol FG, and b) about 3 wt % Fluorolink 7004, and c) about 38 wt % perfluoropolyether; and d) about 33 wt % poly(tetrafluoroethylene).
 52. A topical skin protectant formulation of claim 2 comprising: a) about 21 wt % Lupasol FG, and b) about 5 wt % Dytek EP, and c) about 3 wt % Fluorolink 7005, and d) about 38 wt % perfluoropolyether; and e) about 33 wt % poly(tetrafluoroethylene).
 53. A topical skin protectant formulation of claim 2 comprising: a) about 17 wt % Lupasol LU, and b) about 2 wt % Fluorolink 7005, and c) about 4 wt % water and d) about 31 wt % perfluoropolyether; and e) about 46 wt % poly(tetrafluoroethylene).
 54. A topical skin protectant formulation of claim 2 comprising: a) about 23 wt % Lupasol LU, and b) about 3 wt % Fluorolink 7005, and c) about 35 wt % perfluoropolyether; and d) about 40 wt % poly(tetrafluoroethylene).
 55. A topical skin protectant formulation of claim 2 comprising: a) about 20 wt % Lupasol LU, and b) about 1 wt % Fluorolink 7004, and c) about 5 wt % water and d) about 38 wt % perfluoropolyether; and e) about 35 wt % poly(tetrafluoroethylene).
 56. A topical skin protectant formulation of claim 2 comprising: a) about 25 wt % Lupasol LU, and b) about 2 wt % Fluorolink 7004, and c) about 38 wt % perfluoropolyether; and d) about 35 wt % poly(tetrafluoroethylene).
 57. A topical skin protectant formulation of claim 2 comprising: a) about 13 wt % Lupasol FG, and b) about 13 wt % Lupasol WF, and c) about 1.5 wt % Fluorolink 7004, and d) about 1.5 wt % Fluorolink 7005, and e) about 38 wt % perfluoropolyether; and f) about 33 wt % poly(tetrafluoroethylene).
 58. A topical skin protectant formulation of claim 2 comprising: a) about 5 wt % Dytek EP, and b) about 1 wt % Fluorolink 7005, and c) about 49 wt % perfluoropolyether; and d) about 45 wt % poly(tetrafluoroethylene).
 59. A topical skin protectant formulation of claim 2 comprising: a) about 5 wt % Dytek EP, and b) about 1 wt % Fluorolink 7004, and c) about 49 wt % perfluoropolyether; and d) about 45 wt % poly(tetrafluoroethylene).
 60. A topical skin protectant formulation of claim 2 comprising: a) about 13 wt % Lupasol WF, and b) about 13 wt % Lupasol FG, and c) about 3 wt % Fluorolink 7005, and d) about 38 wt % perfluoropolyether; and e) about 33 wt % poly(tetrafluoroethylene).
 61. A topical skin protectant formulation of claim 2 comprising: a) about 13 wt % Lupasol WF, and b) about 13 wt % Lupasol G20, and c) about 3 wt % Fluorolink 7005, and d) about 38 wt % perfluoropolyether; and e) about 33 wt % poly(tetrafluoroethylene).
 62. A topical skin protectant formulation of claim 2 comprising: a) about 13 wt % Lupasol WF, and b) about 13 wt % Lupasol SC, and c) about 3 wt % Fluorolink 7005, and d) about 38 wt % perfluoropolyether; and e) about 33 wt % poly(tetrafluoroethylene).
 63. A topical skin protectant formulation of claim 2 comprising: a) about 13 wt % Lupasol P, and b) about 13 wt % Lupasol WF, and c) about 3 wt % Fluorolink 7005, and d) about 38 wt % perfluoropolyether; and e) about 33 wt % poly(tetrafluoroethylene).
 64. A topical skin protectant formulation of claim 2 comprising: a) about 13 wt % Lupasol P, and b) about 13 wt % Lupasol FG, and c) about 3 wt % Fluorolink 7005, and d) about 38 wt % perfluoropolyether; and e) about 33 wt % poly(tetrafluoroethylene).
 65. A topical skin protectant formulation of claim 2 comprising: a) about 14 wt % Lupasol P, and b) about 13 wt % Lupasol G20, and c) about 3 wt % Fluorolink 7005, and d) about 38 wt % perfluoropolyether; and e) about 33 wt % poly(tetrafluoroethylene).
 66. A topical skin protectant formulation of claim 2 comprising: a) about 13 wt % Lupasol P, and b) about 13 wt % Lupasol SC, and c) about 3 wt % Fluorolink 7005, and d) about 38 wt % perfluoropolyether; and e) about 33 wt % poly(tetrafluoroethylene).
 67. A topical skin protectant formulation of claim 2 comprising: a) about 13 wt % Lupasol FG, and b) about 13 wt % Lupasol SC, and c) about 3 wt % Fluorolink 7005, and d) about 38 wt % perfluoropolyether; and e) about 33 wt % poly(tetrafluoroethylene).
 68. A topical skin protectant formulation of claim 2 comprising: a) about 13 wt % Lupasol SC, and b) about 13 wt % Lupasol G20, and c) about 3 wt % Fluorolink 7005, and d) about 38 wt % perfluoropolyether; and e) about 33 wt % poly(tetrafluoroethylene).
 69. A topical skin protectant formulation of claim 2 comprising: a) about 11 wt % Lupasol G20, and b) about 12 wt % Lupasol FG, and c) about 3 wt % Fluorolink 7005, and d) about 34 wt % perfluoropolyether; and e) about 40 wt % poly(tetrafluoroethylene).
 70. A topical skin protectant formulation of claim 2 comprising: a) about 13 wt % Lupasol LU, and b) about 13 wt % Lupasol G20, and c) about 3 wt % Fluorolink 7005, and d) about 38 wt % perfluoropolyether; and e) about 33 wt % poly(tetrafluoroethylene).
 71. A topical skin protectant formulation of claim 2 comprising: a) about 13 wt % Lupasol LU, and b) about 13 wt % Lupasol WF, and c) about 3 wt % Fluorolink 7005, and d) about 38 wt % perfluoropolyether; and e) about 33 wt % poly(tetrafluoroethylene).
 72. A topical skin protectant formulation of claim 2 comprising: a) about 11 wt % Lupasol LU, and b) about 12 wt % Lupasol SC, and c) about 3 wt % Fluorolink 7005, and d) about 34 wt % perfluoropolyether; and e) about 41 wt % poly(tetrafluoroethylene).
 73. A topical skin protectant formulation of claim 2 comprising: a) about 12 wt % Lupasol LU, and b) about 12 wt % Lupasol P, and c) about 3 wt % Fluorolink 7005, and d) about 35 wt % perfluoropolyether; and e) about 38 wt % poly(tetrafluoroethylene).
 74. A topical skin protectant formulation of claim 2 comprising: a) about 12 wt % Lupasol LU, and b) about 12 wt % Lupasol FG, and c) about 3 wt % Fluorolink 7005, and d) about 36 wt % perfluoropolyether; and e) about 37 wt % poly(tetrafluoroethylene).
 75. A topical skin protectant formulation of claim 2 comprising: a) about 23 wt % PAA-HCL-3L, and b) about 3 wt % Fluorolink 7004, and c) about 34 wt % perfluoropolyether; and d) about 41 wt % poly(tetrafluoroethylene).
 76. A topical skin protectant formulation of claim 2 comprising: a) about 26 wt % PAA-HCL-3L, and b) about 3 wt % Fluorolink 7005, and c) about 38 wt % perfluoropolyether; and d) about 33 wt % poly(tetrafluoroethylene).
 77. A topical skin protectant formulation of claim 2 comprising: a) about 19 wt % PAA-10C, and b) about 1 wt % Fluorolink 7004, and c) about 28 wt % perfluoropolyether; and d) about 52 wt % poly(tetrafluoroethylene).
 78. A topical skin protectant formulation of claim 2 comprising: a) about 18 wt % PAA-10C, and b) about 2 wt % Fluorolink 7005, and c) about 25 wt % perfluoropolyether; and d) about 55 wt % poly(tetrafluoroethylene).
 79. A topical skin protectant formulation of claim 2 comprising: a) about 12 wt % PAA-10C, and b) about 12 wt % PAA-HCL-3L, and c) about 3 wt % Fluorolink 7005, and d) about 34 wt % perfluoropolyether; and c) about 40 wt % poly(tetrafluoroethylene).
 80. A topical skin protectant formulation of claim 2 comprising: a) about 2 wt % DEAM, and b) about 1 wt % Light Surfactant, and c) about 1 wt % water, and d) about 49 wt % perfluoropolyether; and e) about 46 wt % poly(tetrafluoroethylene).
 81. A topical skin protectant formulation of claim 2 comprising: a) about 2 wt % DEAM, and b) about 1 wt % Light Surfactant, and c) about 1 wt % water, and d) about 48 wt % perfluoropolyether; and e) about 48 wt % poly(tetrafluoroethylene).
 82. A topical skin protectant formulation of claim 2 comprising: a) about 2 wt % DEAM, and b) about 1 wt % Light Surfactant, and c) about 1 wt % water, and d) about 49 wt % perfluoropolyether; and e) about 47 wt % poly(tetrafluoroethylene).
 83. A topical skin protectant formulation of claim 2 comprising: a) about 13 wt % Lupasol P, and b) about 13 wt % Lupasol G20, and c) about 1.5 wt % Fluorolink 7004, and d) about 1.5 wt % Fluorolink 7005, and e) about 38 wt % perfluoropolyether; and f) about 33 wt % poly(tetrafluoroethylene).
 84. A topical skin protectant formulation of claim 2 comprising: a) about 13 wt % Lupasol P, and b) about 13 wt % Lupasol FG, and c) about 1.5 wt % Fluorolink 7004, and d) about 1.5 wt % Fluorolink 7005, and e) about 38 wt % perfluoropolyether; and f) about 33 wt % poly(tetrafluoroethylene).
 85. A topical skin protectant formulation of claim 2 comprising: a) about 13 wt % Lupasol G20, and b) about 2 wt % Fluorolink 7005, and c) about 44 wt % perfluoropolyether; and d) about 42 wt % poly(tetrafluoroethylene).
 86. A topical skin protectant formulation of claim 2 comprising: a) about 6 wt % Lupasol G20, and b) about 1 wt % Fluorolink 7005, and c) about 47 wt % perfluoropolyether; and d) about 46 wt % poly(tetrafluoroethylene).
 87. A topical skin protectant formulation of claim 2 comprising: a) about 13 wt % Lupasol WF, and b) about 2 wt % Fluorolink 7005, and c) about 44 wt % perfluoropolyether; and d) about 42 wt % poly(tetrafluoroethylene).
 88. A topical skin protectant formulation of claim 2 comprising: a) about 6 wt % Lupasol WF, and b) about 1 wt % Fluorolink 7005, and c) about 47 wt % perfluoropolyether; and d) about 46 wt % poly(tetrafluoroethylene).
 89. A topical skin protectant formulation of claim 2 comprising: a) about 14 wt % Lupasol G20, and b) about 2 wt % Fluorolink 7004, and c) about 43 wt % perfluoropolyether; and d) about 41 wt % poly(tetrafluoroethylene).
 90. A topical skin protectant formulation of claim 2 comprising: a) about 7 wt % Lupasol G20, and b) about 1 wt % Fluorolink 7004, and c) about 47 wt % perfluoropolyether; and d) about 45wt % poly(tetrafluoroethylene).
 91. A topical skin protectant formulation of claim 2 comprising: a) about 13 wt % Lupasol FG, and b) about 2 wt % Fluorolink 7004, and c) about 44 wt % perfluoropolyether; and d) about 42wt % poly(tetrafluoroethylene).
 92. A topical skin protectant formulation of claim 2 comprising: a) about 7 wt % Lupasol FG, and b) about 2 wt % Fluorolink 7004, and c) about 47 wt % perfluoropolyether; and d) about 46 wt % poly(tetrafluoroethylene).
 93. A topical skin protectant formulation of claim 2 comprising: a) about 13 wt % Lupasol FG, and b) about 2 wt % Fluorolink 7005, and c) about 44 wt % perfluoropolyether; and d) about 41 wt % poly(tetrafluoroethylene).
 94. A topical skin protectant formulation of claim 2 comprising: a) about 7 wt % Lupasol FG, and b) about 1 wt % Fluorolink 7005, and c) about 47 wt % perfluoropolyether; and d) about 46 wt % poly(tetrafluoroethylene).
 95. A topical skin protectant formulation of claim 2 comprising: a) about 7 wt % Lupasol FG, and b) about 7 wt % Lupasol WF, and c) about 1 wt % Fluorolink 7004, and d) about 1 wt % Fluorolink 7005, and e) about 44 wt % perfluoropolyether; and f) about 42 wt % poly(tetrafluoroethylene).
 96. A topical skin protectant formulation of claim 2 comprising: a) about 3 wt % Lupasol FG, and b) about 3 wt % Lupasol WF, and c) about 0.5 wt % Fluorolink 7004, and d) about 0.5 wt % Fluorolink 7005, and e) about 49 wt % perfluoropolyether; and f) about 47 wt % poly(tetrafluoroethylene).
 97. A topical skin protectant formulation of claim 2 comprising: a) about 13 wt % Lupasol P, and b) about 1.5 wt % Fluorolink 7005, and c) about 45 wt % perfluoropolyether; and d) about 41 wt % poly(tetrafluoroethylene).
 98. A topical skin protectant formulation of claim 2 comprising: a) about 6 wt % Lupasol P, and b) about 1 wt % Fluorolink 7005, and c) about 48 wt % perfluoropolyether; and d) about 45 wt % poly(tetrafluoroethylene).
 99. A topical skin protectant formulation of claim 2 comprising: a) about 15 wt % Lupasol WF, and b) about 2 wt % Fluorolink 7004, and c) about 51 wt % perfluoropolyether; and d) about 33 wt % poly(tetrafluoroethylene).
 100. A topical skin protectant formulation of claim 2 comprising: a) about 14 wt % Lupasol P, and b) about 2 wt % Fluorolink 7004, and c) about 48 wt % perfluoropolyether; and d) about 36 wt % poly(tetrafluoroethylene).
 101. A topical skin protectant formulation of claim 2 comprising: a) about 17 wt % Lupasol WF, and b) about 1 wt % Fluorolink 7004, and c) about 50 wt % perfluoropolyether; and d) about 41 wt % poly(tetrafluoroethylene).
 102. A topical skin protectant formulation of claim 2 comprising: a) about 7 wt % Lupasol P, and b) about 1 wt % Fluorolink 7004, and c) about 49 wt % perfluoropolyether; and d) about 43 wt % poly(tetrafluoroethylene).
 103. A topical skin protectant formulation of claim 2 comprising: a) about 13 wt % Lupasol P, and b) about 13 wt % Lupasol WF, and c) about 1.5 wt % Fluorolink 7004, and d) about 1.5 wt % Fluorolink 7005, and e) about 38 wt % perfluoropolyether; and f) about 33 wt % poly(tetrafluoroethylene).
 104. A topical skin protectant formulation of claim 2 comprising: a) about 13 wt % Lupasol G20, and b) about 13 wt % Lupasol FG, and c) about 1.5 wt % Fluorolink 7004, and d) about 1.5 wt % Fluorolink 7005, and e) about 38 wt % perfluoropolyether; and f) about 33 wt % poly(tetrafluoroethylene).
 105. A topical skin protectant formulation of claim 2 comprising: a) about 13 wt % Lupasol G20, and b) about 13 wt % Lupasol WF, and c) about 1.5 wt % Fluorolink 7004, and d) about 1.5 wt % Fluorolink 7005, and e) about 38 wt % perfluoropolyether; and d) about 33 wt % poly(tetrafluoroethylene).
 106. A topical skin protectant formulation for neutralizing chemical warfare agents into less toxic products comprising: a) a barrier base cream, said barrier base cream comprising about 20-50 wt % poly(tetrafluoroethylene) resins dispersed in 30-60 wt % perfluorinated polyether oils; b) 1-30 wt % of one or more active moieties comprising: (a) Lupasol P (b) Lupasol WF (c) Lupasol G20 (d) Lupasol SC, (e) Lupasol G20, (f) Lupasol LU, (g) Dytek EP, (h) homopolymer of 2-propen-1-amine hydrochloride (PAA-HCL-3L), (i) homopolymer of 2-propen-1-amine (PAA-10C), and (j) diethanolamine modified; c) one or more additives.
 107. The topical skin protectant formulation of claim 106, having a viscosity is 20 cSt to 500 cSt.
 108. The topical skin protectant formulation of claim 106, having a surface area of 6 m²/g.
 109. The topical skin protectant formulation of claim 106, wherein said active moiety is in said base cream as a solid or aqueous suspension.
 110. A topical skin protectant formulation for neutralizing chemical warfare agents into less toxic products comprising: one or more active moieties, said one or more active moieties comprising (a) Lupasol P (b) Lupasol WF (c) Lupasol G20 (d) Lupasol SC, (e) Lupasol G20, (f) Lupasol LU, (g) Dytek EP, (h) homopolymer of 2-propen-1-amine hydrochloride (PAA-HCL-3L), (i) homopolymer of 2-propen-1-amine (PAA-10C), and (j) diethanolamine modified.
 111. A topical skin protectant formulation of claim 2 comprising: a) about 10 wt % Lupasol P, and b) about 2 wt % Fluorolink 7004, and c) about 7 wt % water, and d) about 38 wt % perfluoropolyether; and e) about 43 wt % poly(tetrafluoroethylene).
 112. A topical skin protectant formulation of claim 2 comprising: a) about 15 wt % Lupasol P, and b) about 3 wt % Fluorolink 7004, and c) about 6 wt % water, and d) about 27 wt % perfluoropolyether; and e) about 49 wt % poly(tetrafluoroethylene). 